The STAMPEDE trial: paradigm-changing data through innovative trial design.

about

The STAMPEDE trial: paradigm-changing data through innovative trial design.

Item

http://www.wikidata.org/entity/Q36163344

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@ast

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@en

type

Item

label

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@ast

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@en

prefLabel

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@ast

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@en

P1476

The STAMPEDE trial: paradigm-changing data through innovative trial design.

@en

P2093

Bradley C Carthon

http://www.w3.org/2001/XMLSchema#string

Emmanuel S Antonarakis

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

P304

S485-S490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TCR.2016.09.08

http://www.w3.org/2001/XMLSchema#string

P433

3 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27738594

http://www.w3.org/2001/XMLSchema#string

P932

5058354

http://www.w3.org/2001/XMLSchema#string